[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemia-lymphoid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemia-lymphoid":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100555791","phase-2-efficacy-of-risk-stratified-treatment-in-newly-diagnosed-infant-leukemia-100555791",false,"NCT06516679","Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia","Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia: A Multicenter, Prospective Study","Inclusion Criteria:\n\n* The age of diagnosis is less than 1 year old\n* The disgnosisi of ALL or ALAL(lymphoid predominant)\n* Informed consent of the parents(guardians) before participation in this study\n\nExclusion Criteria:\n\n* Burkitt leukemia\u002Flymphoma or mature B-cell leukemia\n* Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachman syndrome or other bone marrow failure syndrome, hematopoietic stem cell transplantation\n* Relapsed infant leukemia\n* Participants with contraindication to medication\n* Administered systemic steroid therapy within 4 weeks prior to this study (However, steroid administration is allowable in oncologic emergencies only after the subject's disease diagnosis and risk group classification are completed.)\n* Participants in other interventional studies other than this protocol","ALL","2 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This clinical trial is an open-label, multicenter, prospective phase 2 clinical trial targeting pediatric leukemia patients of infant age. The goal is to improve survival rates by varying the presence or absence of chemotherapy and hematopoietic stem cell transplantation based on genetic characteristics at the time of diagnosis and minimal residual disease (MRD) values measured by various methods after treatment.\n\nIn addition, by clearly defining the patient group that requires hematopoietic stem cell transplantation, it is expected that the role of hematopoietic stem cell transplantation in infantile leukemia, for which there have been various guidelines for hematopoietic stem cell transplantation, can be confirmed. Additionally, due to the characteristics of infants, this study aim to identify long-term sequelae or prognosis related to treatment by prospectively collecting side effect data related to treatment during and after treatment.",[26],"Leukemia, Lymphoid","RECRUITING","2026-07-28",{"date":30,"type":31},"2026-07-29","ACTUAL",{"date":33,"type":31},"2024-12-11",{"date":35,"type":20},"2032-12-31",{"name":37,"class":38},"Yonsei University","OTHER",10,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":63},"100524660","phase-2-short-term-blinatumomab-as-a-bridge-therapy-for-allo-hsct-in-low-burden-b-all-100524660","NCT06111625","Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL","Short-term Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in B-cell Acute Lymphoblastic Leukemia With Low Leukemia Burden","Inclusion Criteria:\n\n1. patients diagnosed with B-ALL;\n2. patients with age ≥ 16 years;\n3. Availability of both pre- and post-transplantation disease status records.\n\nExclusion Criteria:\n\n1. administration of blinatumomab therapy for more than 14 days;\n2. patients with leukemia burden ≥ 10% before initiation of treatment;\n3. patients with severe organ dysfunctions before treatment, including myocardial infarction, chronic heart failure, decompensated liver dysfunction, renal dysfunction, or gastrointestinal dysfunction;\n4. patients with central nervous system leukemia.","16 Years","65 Years",{"count":50,"type":20},20,[23],"The goal of this single-arm, prospective study is to test in low-burden B-cell lymphoblastic leukemia (B-ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is:\n\n• The efficacy and safety of short-term blinatumomab as a bridging therapy to allo-HSCT in patients with low-burden B-ALL. Participants will take intravenous blinatumomab prior to allo-HSCT with an initial dosage of 8 μg\u002Fday. The dosage gradually escalated to 28 μg\u002Fday and continued for 5 to 10 days. Dexamethasone 20mg was administered 1 hour before the onset of blinatumomab infusion.",[26],"2023-10-27",{"date":56,"type":31},"2023-11-01",{"date":58,"type":31},"2023-09-10",{"date":60,"type":20},"2026-08-31",{"name":62,"class":38},"Sichuan University",1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":63},"100521872","phase-2-blinatumomab-prevents-recurrence-of-rr-all-after-allo-hsct-100521872","NCT06075238","Blinatumomab Prevents Recurrence of R\u002FR ALL After Allo-HSCT","Blinatumomab Prevents the Recurrence of Relapsed or Refractory Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem-cell Transplantation: A Prospective, Singlecentered, Single-arm, Phase II Clinical Study","Inclusion Criteria:\n\n1. B-ALL patients with history of relapse, or MRD positive in the last bone marrow examination before allo-HSCT;\n2. Age ≥16 years old and ≤ 65 years old when signing informed consent Form (ICF);\n3. KPS \\> 60 or ECOG 0-2;\n4. The expected survival time is more than 3 months;\n5. Complete remission (CR) after allo-HSCT with either myeloablative or non-myeloablative conditioning regimen determined by the investigator;\n6. Reach the standard of hematopoietic reconstitution (neutrophil count\n\n   ≥ 0.5×10\\^9\u002FL for 3 consecutive days without G-CSF application, platelet count ≥ 20×10\\^9\u002FL for 7 consecutive days without platelet transfusion, Hb ≥ 80 g \u002FL without red blood cell transfusion); and neutrophil count ≥ 1.5×10\\^9\u002FL, platelet count ≥ 50×10\\^9\u002FL within 45 days after transplantation;\n7. No central nervous system involvement or clinical symptoms after transplantation;\n8. Those who have no serious functional damage to important organs of the body;\n9. Fully understand and be informed of this study and sign the ICF; willing to follow and have the ability to complete all test procedures;\n10. Females of childbearing age must afford a serum pregnancy test within 7 days before the first dose, and the result should be negative; female participants and their partners should agree to use effective contraception from signing the ICF until 6 months after the last dose.\n\nExclusion Criteria:\n\n1. Serious basic diseases of important organs: such as myocardial infarction, chronic cardiac insufficiency, decompensated hepatic insufficiency, renal function, gastrointestinal insufficiency, etc.;\n2. Uncontrolled active infection (including bacterial, fungal, or viral infection), and drug treatment is ineffective;\n3. Participating in other clinical studies, or planning to start treatment in this study and less than 4 weeks before the end of treatment in the previous clinical study;\n4. Poor graft function (PGF) occurred after allo-HSCT;\n5. Combined with other malignant tumors and require treatment;\n6. Active GVHD;\n7. Have a history of allergy to Chidamide;\n8. Pregnant or lactating females;\n9. Patients with known history of human immunodeficiency virus (HIV) virus infection and\u002For acquired immunodeficiency syndrome;\n10. Patients with active chronic hepatitis B or active hepatitis C;\n11. History of prolonged QT syndrome;\n12. Patients considered by other researchers to be unsuitable for this study",{"count":72,"type":20},68,[23],"The goal of this phase I\u002FII clinical trial is to test in relapsed or refractory acute lymphoblastic leukemia (R\u002FR ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is:\n\n• The efficacy and safety of blinatumomab maintenance therapy in reducing the recurrence rate a in R\u002FR ALL patients after allo-HSCT. Participants will take intravenous blinatumomab after allo-HSCT. The dose of one course was as follows: day 1-2: 8ug\u002Fday, continuous intravenous drip for 24 hours, day 3-7: 16ug\u002Fday, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.",[26],"NOT_YET_RECRUITING","2023-10-03",{"date":79,"type":31},"2023-10-10",{"date":81,"type":20},"2023-10-01",{"date":83,"type":20},"2026-09-30",{"name":62,"class":38}]